Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for posting. I think Oncosec's PISCES BORR will improve as more patients are evaluated and hit the 30% mark. The fact that the patients in PISCES are confirmed checkpoint failed patients is the key here (other company trials are likely skewing their actual response numbers higher). It is a salvage therapy and according to Oncosec is the quickest way to an approval. They have a good shot in my opinion. Other trials are starting as well and a new product candidate is coming soon makes Oncosec more interesting with regards to overall pipeline. TNBC could be a real winner too. About the STAT article, I remember AF pointing out in his previous article how significant the one confirmed checkpoint failed patient was. Now Oncosec is backing that previous data up with more responders (previously confirmed checkpoint failures) to TAVO/checkpoint....with time this therapy works for patients that have no other choice left.....so I would be positive about the current state of the PISCES trial.
Serious growth path ahead for Digipath. They should consider an uplist to a major exchange. The growth in cannabis is too huge to ignore and all cannabis needs to be tested. Revenue will continue to increase for this company.
Looks like DIGP is getting ready to move higher. Just a matter of time. Prospects look good.
New STAT article on Oncosec. If anybody has the info please post it. Thanks! https://www.statnews.com/2019/02/08/small-cap-biotech-bellus-health-oncosec-medical/
Oncosec Head and Neck trial is now posted on clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT03823131 It is an IST trial so no cost to Oncosec, shareholders should be pleased with that.
DigiPath, Inc.- MoneyTV with Donald Baillargeon https://vimeo.com/314674104?ref=em-share
Revenues have increased this year to 2.8 mil. With expansion of labs at HEMP locations and also Colombia market soon I would expect revenues will continue on an upwards trajectory. All cannabis needs to be tested so Digipath should do well.
Executives recently granted new stock options recently to replace old options. Think they are anticipating good things this year.
Oncosec has indicated that front-line therapy is where this will be headed. The need to treat patients at an earlier stage of their disease with TAVO would obviously be the wise choice when patients have a stronger immune sytsem. This is what should have been done in the first place; a head to head study with two arms of patients, one with just Keytruda vs. a second arm with TAVO + Keytuda. The planned trial with Opdivo would be a front-line indication (neoadjuvant setting).
This is good news but so far the links and navagation don't go anywhere on the website.
we should see some new quarterly filings within the next 10 days.
Good points Danger. That 20% instead of 30% bar is very likely to get Oncosec a PISCES approval if they come in at around 24% BORR....although I think it will move up to the 30% or higher range with time. Along the way we should expect preliminary data from TNBC to give Oncosec a share boost and market confidence that they are on the way to multiple fda approvals in time. Earlier partnering or buyout will be on the table....because it is a possibility at any time. Nobody knows what plans Merck has, but if Oncosec continues to produce convincing data as it matures you can bet Merck will be more likely to pull the trigger. If they did not have faith in Oncosec they would not be involved in yet another trial, which will make three trials going in combo with Oncosec....and then Head and Neck will make 4 when that gets under way. When Merck loses interest they cancel trials not increase them like they are doing with Oncosec.
CEO just said Oncosec will be presenting at AACR.
PISCES trial showing progress. 24% BORR is above the 20% bar for approval. Oncosec is turning into an Orphan Drug Company with pipeline expansion. Very likely to see a buyout before end of PISCES trial....Merck (combo studies with Oncosec growing)
looking over their financials, they should be in much better shape this year. They took a hit last year due to temporary license suspension and need to upgrade equipment to meet testing standards. All seems to be in order now and the financial hit from last year was a one-off issue.
HEMP is expanding to 6 more cities soon and the three Digipath Labs to be built at current locations will be at no cost to Digipath, and they will be owned by Digipath. You can't beat that. I would expect HEMP to open Digipath labs at every new location they expand to in the future if this partnership works out well in the first 3 sites.
dilution is always something to be on the lookout for. Looking at the chart this has the potential to hit .50-.60 or higher on good news if it can break resistance around .31.
Are they looking at government funding for Colombian operations?
With the move this stock has made in the past week I would expect some pullback. Fact is that Digipath will expand with the help of HEMP and Colombia expansion looks very promising too. Lots of potential here. I like it. Testing labs are another angle to play the huge Weed sector...only going to get better.
It's going right back up. no worries. This wants higher prices based on company expansion...that is fundamental reason to stick with this.
If data was not moving in the right direction Merck would not agree to yet another trial , this time for cervical cancer. That will be 4 trials going soon if you include Head and Neck cancer. When trials are not going well Merck abandons them. Oncosec has the potential to go on a monster run with promising data in the hardest to treat patient populations....they will get approvals.
Expanding to Colombia sounds very good for this company. I am wondering if they would be able to secure government funding for operations or other forms of non-dilutive funding for this expansion?
Oncosec solidly broke above the 50-day today at .75. They presented at NobleCon15 yesterday so maybe some good news was shared there and new investors may have jumped in. The 100-day is $1.10. Hopefully the conference call friday lifts ONCS above that $1 mark and keeps it there. Once the delisting fear subsides the price will likely move back to where it was before the massive selloff happened. As long as PISCES data progresses in a positive way we should be in good shape.
my gut is telling me this stock wants higher prices. A break above .03 and I think we will get a strong spike. The move will show up on radar and people will pile in temporarily. I'll take a small shot at it.
I am a cat person myself but PHYTO-BITES CBD for Dogs looks like an interesting product to sell. If anything this will be fun to watch for a while. The market is nuts for anything CBD so if the right news hits....I could see this make a quick spike.
Thanks for the insight. I will be watching this closely.
I am simply looking at the one month chart which looks like a bullish penant flag consolidating and possibly ready for a breakout.
I'll give it a shot here with a very small investment....what the heck. They are charging $60 for a pack of CBD water and they say that is their best seller. Maybe they catch some lightning and shares spike.
I am new to this company, so I don't know. Seems like they are making some strategic moves in the CBD space. With all the interest in cannabis stocks, SING looks like it could make a strong move soon. Long chart suggest a spike to .12 possibly.
This looks interesting: "Fit Fresh Foods, HIPH announced that it had entered into a distribution agreement with SinglePoint (OTC: SING) subsidiary SingleSeed"
Looking for a partner or partners for multi-gene construct in my opinion. An exclusive licensing deal with another big pharma for this new future disruptive tech would take the market by surprise. A few $100 mil licensing deal would spike Oncosec shares.....a real possibility not be factored into shares right now.
APHRIA....GAP UP....GREEN!....suckers sold earlier today. $10 price target initiated today. Top grower along with Canopy and Cron. APHA...Going much higher!
Aphria $10 price target initiated at CIBC https://www.msn.com/en-us/money/news/cibc-initiates-coverage-on-cannabis-stocks-sees-bright-future-ahead/ar-BBSqB1z
Aphria may have just experienced a Bear Raid. Think some decent news hits very soon. Serious partnering in the works likely.
BOUNCE TIME! suckers sold....going right back up.
Expecting a strong bounce right here around $6.30.
The market must agree because if there was any truth to the allegations Aphria stock would be under a buck. They still have a $1.6 billion market cap. 255,000 kg is alot of weed production coming this year.
Aphria needs to get a reputable CEO in position ASAP and strike a deal with a big beverage or tobacco company.....then this rocks 100% in a day. I agree Green Growth looks like a rediculous alternative.
Green Growth Brands stock is spiking today. Aphria shares should rebound too. At current value a takeover of Aphria would be $1 above current share APHA price if bid price is still the same. Not sure what is true and what is false with all the news but I do think Aphria shares should be much higher if they are able to produce 255,000 kg of weed this year......now Green Growth shares are dropping again.....minutes later....weed stocks are crazy!